We previously demonstrated p53 heterozygosity and greater induction of p53 expression by the DNA damaging agent doxorubicin in Wnt-1 p53+/− tumor cells relative to Wnt-1 p53+/− tumor cells [21], [32]. The gene discussed is TP53; the disease is neoplasm.